These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28745547)

  • 1. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
    Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
    Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of
    Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
    Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
    Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
    Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
    Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.
    Gautier-Veyret E; Fonrose X; Stanke-Labesque F
    Clin Pharmacol Ther; 2017 Aug; 102(2):189. PubMed ID: 28182291
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".
    Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
    Clin Pharmacol Ther; 2018 Feb; 103(2):187. PubMed ID: 28786218
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of
    Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
    Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP3A4 Genotype on Voriconazole Exposure.
    Duflot T; Schrapp A; Bellien J; Lamoureux F
    Clin Pharmacol Ther; 2018 Feb; 103(2):185-186. PubMed ID: 28786228
    [No Abstract]   [Full Text] [Related]  

  • 11. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
    Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
    Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
    Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
    Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
    Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.
    Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
    Clin Pharmacol Ther; 2017 Aug; 102(2):190. PubMed ID: 28455946
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
    Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
    Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.